5-fluorouracil,oxaliplatin,Irinotecan
Not Tagged
[]
norpact-1 trial with dr. labori, short course neoadjuvant folfirinox x4 vs upfront surgery in pdac. neoadjuvant group did worse (os 25.1 vs 38.5 months) hr 1.52 (p=0.096). median os 23 vs 34.4 months. #asco2023 
Medical oncologist: GI cancers & cancer of unknown primary + high quality & value-based cancer care delivery. @UTexasValue MSHCT student. Tweets mine.